1 of 3,890

Weight loss drug Zepbound prevents diabetes, Lilly says


Drug giant Eli Lilly says its weight-loss drug tirzepatide helps people with obesity avoid getting diabetes, even months after stopping the medication.

Excess weight increases the risk for diabetes and losing weight reduces that risk, but substantial weight loss has been so challenging that few people manage it for long. A new class of medications, called GLP-1s, including tirzepatide, which Lilly sells as Zepbound for weight loss, is the first effective treatment for many people.

The three-year study, known as SURMOUNT-1, showed people with pre-diabetes who took the highest dose, a weekly 15 mg shot, lost nearly 23% of their body weight on average. Their risk of developing diabetes was 94% lower than people with pre-diabetes who received a placebo and lost about 2% of their body weight on average, according to a company press release.



Read More

Leave a comment